公开(公告)号：US20120115735A1

公开(公告)日：2012-05-10

申请号：US13060453

申请日：2009-09-03

申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Xiaosong Zhang ,  Jimmy Cheng-Ho Lin ,  Rebecca J. Leary ,  Philipp Angenendt ,  Nickolas Papadopoulos ,  Victor Velculescu ,  Giovanni Parmigiani ,  Rachel Karchin ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein

发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Xiaosong Zhang ,  Jimmy Cheng-Ho Lin ,  Rebecca J. Leary ,  Philipp Angenendt ,  Nickolas Papadopoulos ,  Victor Velculescu ,  Giovanni Parmigiani ,  Rachel Karchin ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein

IPC分类号： C12Q1/68 ,  C40B20/00 ,  C07H21/04

CPC分类号： G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2800/50

摘要： There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples. The data suggest that dysregulation of this core set of pathways is responsible for the major features of pancreatic tumorigenesis.

摘要翻译： 目前对胰腺癌患者几乎没有治疗选择，迫切需要对这种致死性疾病的发病机理的新见解。 为此，我们对24个胰腺肿瘤中改变的基因进行了综合分析。 首先，我们从这些肿瘤的DNA中确定了23,781个转录本，代表20,583个蛋白质编码基因的序列。 第二，我们使用微阵列查询每个样本中的百万个单核苷酸多态性的纯合缺失和扩增。 第三，我们使用SAGE和下一代按序合成技术分析了相同样品的转录组。 我们发现胰腺癌平均存在63个遗传改变，其中49个是点突变，8个是纯合缺失，6个是扩增。 进一步的分析揭示了一组核心的12个调节过程或途径，在70％至100％的样品中进行了遗传改变。 数据表明，这种核心途径的失调导致了胰腺肿瘤发生的主要特征。

公开(公告)号：US20120034318A1

公开(公告)日：2012-02-09

申请号：US13254610

申请日：2010-03-05

申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

IPC分类号： A61K33/24 ,  A61P35/00 ,  C40B20/08 ,  G01N33/577 ,  G01N33/566 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  A61K31/407 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N2333/47

摘要： The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

摘要翻译： 本发明提供了一种检测胰腺癌患者和具有胰腺癌家族史的个体中PALB2基因突变的方法。 还提供了用于诊断患有胰腺癌的倾向，用于预测患者对胰腺癌治疗的反应以及用于治疗患者胰腺癌的方法，其基于在患者体内PALB2突变或异常PALB2基因表达的存在。

公开(公告)号：US09115403B2

公开(公告)日：2015-08-25

申请号：US13254610

申请日：2010-03-05

申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

IPC分类号： C12Q1/68 ,  C12P19/34 ,  A61P35/00 ,  G01N33/574 ,  C07H21/04

摘要： The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

公开(公告)号：US09315868B2

公开(公告)日：2016-04-19

申请号：US13254610

申请日：2010-03-05

申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  D. Williams Parsons ,  Sian Jones ,  Scott Kern ,  Ralph Hruban ,  James R. Eshleman ,  Michael Goggins ,  Alison Klein ,  Manuel Hidalgo ,  Victor E. Velculescu

IPC分类号： C12Q1/68 ,  C12P19/34 ,  A61P35/00 ,  G01N33/574 ,  C07H21/04

CPC分类号： C12Q1/6886 ,  A61K31/407 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N2333/47

摘要： The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

摘要翻译： 本发明提供了一种检测胰腺癌患者和具有胰腺癌家族史的个体中PALB2基因突变的方法。 还提供了用于诊断患有胰腺癌的倾向，用于预测患者对胰腺癌治疗的反应以及用于治疗患者胰腺癌的方法，其基于在患者体内PALB2突变或异常PALB2基因表达的存在。

公开(公告)号：US11082418B2

公开(公告)日：2021-08-03

申请号：US15895682

申请日：2018-02-13

申请人： Mark A. Nelson ,  George S. Rathbun ,  Scott Kern

发明人： Mark A. Nelson ,  George S. Rathbun ,  Scott Kern

IPC分类号： H04L29/06 ,  H04L9/32

摘要： A system, method, apparatus, and computer program product for a privacy ensured brokered identity federation system. The privacy ensured brokered identity federation system connects a user in a brokered identity federation environment that blinds relying parties (RP) from credential service providers (CSP), blinds CSPs from RPs, and blinds a user's identity and data from the federation middleware hubs. The system utilizes ring signatures to attest to CSPs that a valid RP of the federation is making a request. The process utilizes CSP ring signatures to assure RPs that a valid CSP of the federation has provided a response. The process utilizes per transaction encryption keys created by the RP to ensure the federation has no access to data messages. It can further ensure that only the correct RP can decrypt a CSP response.

公开(公告)号：US20070055419A1

公开(公告)日：2007-03-08

申请号：US11593002

申请日：2006-11-06

申请人： Ronald List ,  Scott Kern ,  Howard Lang ,  James Zecca

发明人： Ronald List ,  Scott Kern ,  Howard Lang ,  James Zecca

IPC分类号： G05D1/00

CPC分类号： B63H21/213

摘要： A control system for a marine vessel having three or more engines is disclosed. The three or more engines may be operated via one or two control levers from each of one or more control stations. The control system may include a first control lever and a second control lever, each of which has an associated operating range. The control levers operate the engine throttle and transmission controls for three or more engines in a plurality of modes. This may be accomplished under software control using a digital data link between respective engine control units associated with the engines.

摘要翻译： 公开了一种具有三个或更多个发动机的船舶的控制系统。 三个或更多个发动机可以经由来自一个或多个控制站中的每一个的一个或两个控制杆来操作。 控制系统可以包括第一控制杆和第二控制杆，每个控制杆具有相关联的操作范围。 控制杆操作多个模式中的三个或更多个发动机的发动机节气门和变速器控制。 这可以在软件控制下使用与发动机相关联的各个发动机控制单元之间的数字数据链路来实现。

公开(公告)号：US20060183122A1

公开(公告)日：2006-08-17

申请号：US10540904

申请日：2003-12-26

申请人： Scott Kern ,  Michael Van Der Heijden

发明人： Scott Kern ,  Michael Van Der Heijden

IPC分类号： C12Q1/68

CPC分类号： C07K14/47 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156

摘要： The present invention relates to methods of determining if a patient has cancer or is at increased risk of developing cancer, particularly pancreatic cancer, the method comprising testing a FANC gene for the presence of a cancer-associated coding change, wherein said presence of one or more cancer-associated coding changes is indicative of cancer or an increased risk of cancer in said patient. The invention further relates to methods of treating a patient having cancer, particularly pancreatic cancer, who has one or more cancer-associated coding changes in the FANC genes comprising the step of administering a therapeutically effective amount of a chemotherapeutic cross-linking agent.

摘要翻译： 本发明涉及确定患者是否患有癌症或具有发展为癌症，特别是胰腺癌的风险增加的方法，所述方法包括测试FANC基因以存在癌症相关编码变化，其中所述存在一种或多种 更多的癌症相关的编码变化是所述患者中的癌症或增加的癌症风险的指示。 本发明还涉及治疗患有癌症的患者，特别是胰腺癌的方法，所述患者在FANC基因中具有一种或多种与癌症相关的编码变化，包括给予治疗有效量的化学治疗性交联剂的步骤。

公开(公告)号：US20180234409A1

公开(公告)日：2018-08-16

申请号：US15895682

申请日：2018-02-13

申请人： Mark A. Nelson ,  George S. Rathbun ,  Scott Kern

发明人： Mark A. Nelson ,  George S. Rathbun ,  Scott Kern

IPC分类号： H04L29/06 ,  H04L9/32

CPC分类号： H04L63/0815 ,  H04L9/3255 ,  H04L9/3257 ,  H04L63/0421 ,  H04L63/10 ,  H04L63/12

摘要： A system, method, apparatus, and computer program product for a privacy ensured brokered identity federation system. The privacy ensured brokered identity federation system connects a user in a brokered identity federation environment that blinds relying parties (RP) from credential service providers (CSP), blinds CSPs from RPs, and blinds a user's identity and data from the federation middleware hubs. The system utilizes ring signatures to attest to CSPs that a valid RP of the federation is making a request. The process utilizes CSP ring signatures to assure RPs that a valid CSP of the federation has provided a response. The process utilizes per transaction encryption keys created by the RP to ensure the federation has no access to data messages. It can further ensure that only the correct RP can decrypt a CSP response.

公开(公告)号：US20130074201A1

公开(公告)日：2013-03-21

申请号：US13621460

申请日：2012-09-17

申请人： Scott Kern ,  Francesca Scrimieri

发明人： Scott Kern ,  Francesca Scrimieri

IPC分类号： A61K39/395 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  C12N5/10 ,  C12P21/02 ,  G01N33/574 ,  C12Q1/68 ,  C12N15/113 ,  C07K16/18 ,  A61K31/7088 ,  A61K48/00 ,  A61P35/00 ,  A01K67/027 ,  C12N15/12

CPC分类号： A61K31/713 ,  C07K14/47 ,  C07K16/32 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/5011 ,  G01N33/57484 ,  G01N2500/10

摘要： The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating cancer characterized by the expression of mutant FAM190A proteins. In a specific embodiment, a method for treating a patient having a cancer characterized by a FAM190A intragenic rearrangement comprises the step of administering to the patient an agent that inhibits a biological function or reduces the level or expression of the FAM190A protein.

摘要翻译： 本发明涉及癌症领域。 更具体地，本发明提供了用于治疗癌症的组合物和方法，其特征在于突变型FAM190A蛋白的表达。 在具体实施方案中，用于治疗患有以FAM190A基因内重排为特征的癌症的患者的方法包括向患者施用抑制生物学功能或降低FAM190A蛋白的水平或表达的药剂的步骤。

公开(公告)号：US20060058930A1

公开(公告)日：2006-03-16

申请号：US11250601

申请日：2005-10-17

申请人： Dennis Graham ,  Daniel Carr ,  Scott Kern ,  Howard Lang

发明人： Dennis Graham ,  Daniel Carr ,  Scott Kern ,  Howard Lang

IPC分类号： G05D1/00

CPC分类号： B63H21/21 ,  B63H21/213 ,  B63H21/22 ,  Y10T477/20

摘要： A control system for a marine vessel having one or more engines and a transmission associated with each engine is disclosed. The control system includes one or more control stations, each having a control arm and arm position means coupled to the control arm for providing an electrical signal that represents a position of the control arm within its operating range. The system includes one or more electronic control units, each of which is electro-mechanically coupled to an engine and a transmission. A first electronic control unit (ECU) includes input means for receiving the electrical signal, control means for controlling a throttle of a first engine and shift position of a first transmission based on the electrical signal, and output means for providing a control signal that represents a current position of the control arm to a second ECU. The second ECU is coupled to the first ECU via the communications link, and includes input means for receiving the control signal from the first ECU, and control means for controlling the throttle of a second engine and the shift position of a second transmission based on the power train control signal.